• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    6/29/23 1:37:37 PM ET
    $ADMP
    $ATIP
    $BTAI
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $ADMP alert in real time by email

    Gainers

    • Sigilon Therapeutics (NASDAQ:SGTX) shares rose 506.6% to $23.84 during Thursday's regular session. Trading volume for this security as of 13:37 EST is 4.4 million, which is 53000.3% of its average full-day volume over the last 100 days. The company's market cap stands at $59.6 million.
    • Immunome (NASDAQ:IMNM) shares moved upwards by 33.67% to $7.9. Trading volume for Immunome's stock is 10.5 million as of 13:37 EST. This is 36175.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $96.4 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 28.94% to $3.86. Kintara Therapeutics's stock is trading at a volume of 690.3K shares as of 13:37 EST. This is 1584.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.5 million.
    • Trxade Health (NASDAQ:MEDS) shares moved upwards by 22.97% to $13.22. Trading volume for this security as of 13:37 EST is 221.1K, which is 47.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $134.9 million.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) shares increased by 22.0% to $2.55. Adamis Pharmaceuticals's stock is trading at a volume of 134.3K shares as of 13:37 EST. This is 120.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.7 million.
    • Inovio Pharmaceuticals (NASDAQ:INO) shares rose 18.21% to $0.46. Trading volume for Inovio Pharmaceuticals's stock is 11.2 million as of 13:37 EST. This is 119.2% of its average full-day volume over the last 100 days. The company's market cap stands at $120.2 million.

    Losers

    • BioXcel Therapeutics (NASDAQ:BTAI) stock declined by 65.8% to $6.04 during Thursday's regular session. Trading volume for this security as of 13:37 EST is 17.9 million, which is 3263.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $176.1 million.
    • Cormedix (NASDAQ:CRMD) stock declined by 21.21% to $4.0. As of 13:37 EST, this security is trading at a volume of 3.2 million shares, making up 645.3% of its average full-day volume over the last 100 days. The company's market cap stands at $181.2 million.
    • Liquidia (NASDAQ:LQDA) shares decreased by 19.05% to $8.02. Liquidia's stock is trading at a volume of 2.4 million shares as of 13:37 EST. This is 511.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $518.7 million.
    • ATI Physical Therapy (NYSE:ATIP) shares fell 18.34% to $8.46. ATI Physical Therapy's stock is trading at a volume of 91.4K shares as of 13:37 EST. This is 317.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $35.2 million.
    • Lumos Pharma (NASDAQ:LUMO) shares declined by 17.4% to $3.23. The market value of their outstanding shares is at $26.3 million.
    • Sientra (NASDAQ:SIEN) stock declined by 16.31% to $2.69. The current volume of 938.1K shares is 88.5% of Sientra's average full-day volume over the last 100 days (last updated at 13:37 EST). The company's market cap stands at $30.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $ATIP
    $BTAI
    $CRMD

    CompanyDatePrice TargetRatingAnalyst
    Immunome Inc.
    $IMNM
    2/12/2026$40.00Buy
    H.C. Wainwright
    Immunome Inc.
    $IMNM
    12/1/2025$36.00Buy
    Truist
    CorMedix Inc.
    $CRMD
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    Liquidia Corporation
    $LQDA
    10/20/2025$31.00Overweight
    Wells Fargo
    Immunome Inc.
    $IMNM
    9/22/2025$26.00Buy
    Goldman
    Immunome Inc.
    $IMNM
    9/5/2025$26.00Buy
    Craig Hallum
    Liquidia Corporation
    $LQDA
    8/15/2025$43.00Buy
    Jefferies
    Inovio Pharmaceuticals Inc.
    $INO
    7/9/2025$5.00Overweight
    Piper Sandler
    More analyst ratings

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $149,053 worth of shares (7,278 units at $20.48) and gifted 200,000 shares, decreasing direct ownership by 23% to 660,525 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:38:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technical Officer Tsai Philip bought $204,900 worth of shares (10,000 units at $20.49), increasing direct ownership by 30% to 43,300 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:32:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Humeau Laurent

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    3/5/26 4:55:40 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Shea Jacqueline Elizabeth

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    3/5/26 4:55:11 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Medical Officer Sumner Michael John

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    3/5/26 4:54:42 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale in a registered direct offering of 4,500,785 shares (the "Shares") of common stock, par value $0.001 per share ("Common Stock") (or common stock equivalents in lieu thereof), and accompanying warrants (the "Accompanying Warrants") to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per comm

    3/10/26 2:36:00 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    INOVIO to Participate in Upcoming Scientific Conferences

    PLYMOUTH MEETING, Pa., March 9, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences: Eurogin HPV Conference (Vienna, Austria)Date: Thursday, March 19Time: 8:00 AM CETPresentation: DNA Immunotherapy INO-3107 Demonstrates Long-Term Surgical Intervention Reduction in HPV-6 & 11 RRPWorld Vaccine Congress DC (Washington, DC)Date: Monday, Marc

    3/9/26 8:05:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its fourth quarter and full year 2025 financial results will be released after the market close on March 12, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available

    3/5/26 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Immunome with a new price target

    H.C. Wainwright initiated coverage of Immunome with a rating of Buy and set a new price target of $40.00

    2/12/26 7:24:43 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Immunome with a new price target

    Truist initiated coverage of Immunome with a rating of Buy and set a new price target of $36.00

    12/1/25 8:29:07 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormedix upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Cormedix from Hold to Buy and set a new price target of $14.00

    10/20/25 9:02:46 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    SEC Filings

    View All

    CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CorMedix Inc. (0001410098) (Filer)

    3/6/26 5:07:02 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Liquidia Corporation

    S-3ASR - Liquidia Corp (0001819576) (Filer)

    3/5/26 4:34:36 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Liquidia Corporation

    S-8 - Liquidia Corp (0001819576) (Filer)

    3/5/26 4:32:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    Financials

    Live finance-specific insights

    View All

    INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its fourth quarter and full year 2025 financial results will be released after the market close on March 12, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available

    3/5/26 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    ‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth qu

    3/5/26 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

    BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5th @ 8:30am ETDomestic:   1-844-676-2922International: 1-412-634-6840Webcast:   Webcast Link   About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializi

    3/2/26 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    11/25/24 8:12:55 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ADMP
    $ATIP
    $BTAI
    $CRMD
    Leadership Updates

    Live Leadership Updates

    View All

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Therapeutics Announces Leadership and Board Updates

    BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director. "Under t

    1/8/26 8:05:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care